Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 6/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200186 | 1.00 | VCAM1 (0.47) | VCAM1TDP1ATMMAPTALDH1A1 | |
| Potassium Ion SCHEMBL5158030 | 0.96 | VCAM1 (0.45) | VCAM1TDP1ATMMAPTALDH1A1 | |
| SCHEMBL4614436 | 0.92 | VCAM1 (0.47) | VCAM1TDP1ATMMAPTALDH1A1 | |
| Alcohol SCHEMBL28027621 | 0.90 | TDP1 (0.42) | VCAM1TDP1ATMMAPTALDH1A1 | |
| SCHEMBL1725293 | 0.84 | VCAM1 (0.51) | VCAM1TDP1MAPTALDH1A1HTT | |
| SCHEMBL17304026 | 0.84 | GRIA1 (0.45) | VCAM1TDP1ATMMAPTALDH1A1 | |
| SCHEMBL2870229 | 0.84 | VCAM1 (0.44) | VCAM1TDP1ATMMAPTALDH1A1 | |
| SCHEMBL458453 | 0.84 | VCAM1 (0.44) | VCAM1TDP1MAPTALDH1A1HTT | |
| SCHEMBL2241912 | 0.84 | VCAM1 (0.44) | VCAM1TDP1MAPTALDH1A1HTT | |
| SCHEMBL1291838 | 0.84 | VCAM1 (0.51) | VCAM1TDP1ATMMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4638420-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GASHERBRUM BIO, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-120025279-A | Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 | 格雷沃尔夫治疗有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-119954709-A | Preparation method of sulfoxide compound, aniline compound and preparation method of aniline compound | 帕潘纳(北京)科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119698413-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119677733-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-6399751-B1 | REACTION PRODUCT | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-0784054-B1 | 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVES AND USE AS GLUTAMATE RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMA CO LTD (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-6150379-A | BLOOD COAGULATION FACTOR XA INHIBITORS; TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE ACTIVITY; THROMBOLYTIC AND ISCHEMIC AGENTS; E.G., 2-(6-(5-AMIDINO-1H-BENZIMIDAZOL-2-YL)-PYRID-3-YLCARBONYLAMINO)-3 -HYDROXYBUTYRIC ACID | AXYS PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6096743-A | 1,2,3,4-tetrahydroquinoxalinedione derivative | YAMANOUCHI PHARMACEUTICALS CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| WO-1999026941-A1 | SUBSTITUTED AMIDINOARYL DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | AXYS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0784054-A1 | 1,2,3,4-TETRAHYDROQUINOXALINEDIONE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-07-16 | — | — | EP | disclosed |
| EP-0698024-B1 | [1,2,4]TRIAZOLO [4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1997-01-22 | — | — | EP | disclosed |
| US-5532236-A | TREATMENT OF PARKINSON'S DISEASE | NOVO NORDISK A/S (DK) | 1996-07-02 | — | — | US | disclosed |
| EP-0698024-A1 | 1,2,4]TRIAZOLO 4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026746-A1 | [1,2,4]TRIAZOLO[4,3-a]QUINOXALINE COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | VCAM1 4096/4885TDP1 1179/4885ATM 1077/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | VCAM1 1249/4885TDP1 652/4885ATM 2808/4885 |
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GLP1R, IAPP, GPR119 | VCAM1 745/4885TDP1 1552/4885ATM 4457/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | VCAM1 4004/4885TDP1 1403/4885ATM 991/4885 |
| US-20260035364-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | SCN1B, SCN2B, SCN11A | VCAM1 3618/4885TDP1 3510/4885ATM 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.